Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95. Originally published at CNBC
Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
09,Sep,2023 | Investment | 0 comments